In parenteral processing, Sanhuang Kushen Powder Veterinary Grade API is incorporated into sterile injectable solutions only after the dry extract is assayed for total flavonoid markers as baicalin equivalents; the working formula adjusts the API input to yield 1.2–2.0 mg/mL total flavonoids in the final solution. The manufacturing addition ratio for the raw extract therefore varies from 1.5% w/v to 4.0% w/v depending on lot potency, with a fixed buffer system of 5 mM phosphate at pH 6.0–6.8. Compounding is conducted under ISO 14644-1:2015 Class 8 or better conditions, using Water for Injection at 40°C ±2°C to dissolve the extract without exposing insoluble pectins to high shear. The solution is cooled to 20–25°C, prefiltered through a 0.65 µm polyethersulfone depth filter, and then passed through a 0.22 µm PVDF membrane; terminal steam sterilisation at 121°C is avoided because published data on marker loss in this polysaccharide-rich botanical matrix is limited and process validation is not consistently achieved. Finished sterile injectable products are filled as 10 mL, 20 mL, and 50 mL ampoules or sealed vials for swine and bovine respiratory or enteric dosing forms. Operational boundaries include exclusion of oxidising preservatives, avoidance of pH values below 4.0 where flavonoid aglycones precipitate, and no contact with uncoated stainless steel for more than 8 h due to polyphenol-metal complexation. Compliance references include the current Veterinary Pharmacopoeia of the People’s Republic of China for injectable preparations, VICH GL43 target animal safety documentation, and EU GMP Annex II for botanical-derived active substances.

What Sedimentation and Reconstitution Limits Govern Poultry Water-Soluble Powders?

Manufacture of poultry water-soluble powders from a polysaccharide-rich botanical extract introduces a sedimentation conflict that is resolved through particle size control and buffering. The API is blended with anhydrous citric acid at 1.5–2.5% w/w and sodium bicarbonate at 2.0–3.0% w/w to generate a hydration pH of 4.8–5.2 when added to drinking water. The addition ratio of Sanhuang Kushen Powder in the final dry product is 30–65% w/w, with the remainder consisting of lactose monohydrate, precipitated silica, and a low-foaming surfactant. Dry blending occurs in a double-ribbon mixer at 15–20 rpm for 12–18 min; the mixture is then transferred to a fluid-bed granulator where a 4.0% w/w povidone K30 solution in 30% v/v ethanol is sprayed at 80–120 g/min, inlet air 50–60°C, outlet air 30–38°C, and the dried granulate is screened through 0.8 mm. The terminal finished products are water-soluble powders and reconstitutable granules packaged in 100 g, 250 g, and 500 g LDPE-aluminium foil sachets, intended for broiler, layer, and duck medication through drinking water at a use dilution of 0.5–2.0 g/L. Industry compliance comprises Veterinary Good Manufacturing Practice for powder and granule lines, VICH GL18 for residual solvent evaluation, and water solubility testing according to the Pharmacopoeia of the People’s Republic of China for soluble powders. The operational boundary for stable reconstitution is a water hardness below 250 ppm CaCO₃; above this level 0.1% w/v sodium citrate is added before the product is introduced to avoid calcium-mediated pectin flocculation.

Where high-dose oral delivery through drinking water is required, the API is first dispersed into a preserved aqueous vehicle rather than directly dry-blended. The formulation addition ratio is 1.0–2.5% w/v powdered extract, accompanied by 10–15% w/w propylene glycol and 0.15% w/v sodium benzoate as an oral vehicle preservative; the pH is adjusted to 5.0–6.5 with food-grade citric acid. Production takes place in a conventional liquid oral manufacturing room under ISO 14644-1:2015 Class 9 or equivalent, with high-shear dispersion at 800–1200 rpm for 30–45 min to hydrate plant gum fractions, followed by 50 µm inline filtration to remove undissolved fibre. The final terminal products are oral solutions and drench formulations in 500 mL, 1 L, and 2.5 L HDPE bottles for calves, lambs, and rabbit flocks. Relevant standards include VICH GL18 for residual solvent limits, 21 CFR 211.110 for in-process control of mixing and filling volumes, and stability protocols under VICH GL3 zonal conditions. The operational boundary includes avoiding propylene glycol levels above 20% w/w in neonatal lamb formulations due to hyperosmolarity risk, and preventing storage below 4°C because pectin and polysaccharide fractions can form reversible sedimentation that is not easily redispersed.

When Direct Compression of Sanhuang Kushen Powder Fails Due to Starch-Bound Moisture and Alkaloid Variability

A direct compression route for this API frequently fails batch-to-batch due to alkaloid content variation and moisture uptake above 6% LOD, producing capping and weight variation on high-speed rotary presses. Wet granulation is therefore selected for tableting: the extract is blended as 12–20% w/w of the tablet core with 30–45% w/w microcrystalline cellulose PH102, 10–15% w/w pregelatinised starch, 3–5% w/w povidone K30 as binder, and 2.0% w/w croscarmellose sodium before granulation with a hydroalcoholic binder solution containing 35% v/v ethanol at 20–30% w/w granulating liquid. The wet mass is passed through a 1.2 mm screen and dried in a fluid-bed dryer with inlet air 55–62°C and outlet air 32–38°C to a final moisture of 3.0–4.5% LOD. Compression is performed on a rotary tablet press at 8–15 kN main compression force, 5–8 kp target hardness, and 2–5 mm target thickness for 100 mg and 200 mg scored tablets for companion animals. Terminal products are uncoated or film-coated tablets labeled for canine and feline gastrointestinal disorders. Compliance references include 21 CFR 211 current good manufacturing practice for finished pharmaceuticals, USP <905> uniformity of dosage units, USP <2040> dissolution for botanical tablets, and VICH GL45 stability. Published data for the exact dissolution profile of this botanical tablet under canine gastric pH is limited; therefore the formulation is routinely tested at pH 1.2, pH 4.5, and pH 6.8 to detect abrupt pectin-driven matrix collapse.

Feed Premix Homogeneity, Carryover Limits, and Pellet Conditioning Windows

Premix incorporation of Sanhuang Kushen Powder into pelleted rations is governed by the need to retain marker compounds after conditioning. The API addition ratio in the veterinary premix concentrate is 1.0–3.0% w/w, further diluted in complete feed to 0.5–1.5 kg/t. Manufacturing uses a stepwise dilution sequence: the first blending step combines the extract with 5 kg of ground corncob or defatted rice bran in a 50 kg ploughshare mixer for 8–10 min; the second step combines this intermediate with the bulk carrier in a horizontal ribbon blender at 20–25 rpm for 12–15 min to achieve a coefficient of variation below 5%. Pellet conditioning is restricted to a short-time chamber at 30–40 s and 70–75°C; feed above 80°C has shown marker loss in pilot trials and must be avoided. Terminal feedstock products include 1 kg, 5 kg, and 20 kg foil-lined bags of medicated premix for swine, poultry, and rabbit operations. Compliance for this application is anchored to Regulation (EU) 2019/6 Article 15 for medicated feed, EU GMP Annex II for premix manufacturing, and ISO 22000:2018 for feed safety management. Carryover control after each batch requires cleaning validation with swab limits for matrine and oxymatrine markers; no shared lines with ionophore coccidiostats should be operated without a 6 h intermediate flush cycle. Published data on marker carryover limits for this specific botanical premix configuration is limited, so process validation uses the lowest practicable swab threshold that justifies < 1% cross-contamination in subsequent non-medicated feed.

After wet granulation in a high-shear granulator with impeller speed 150–250 rpm and chopper speed 900–1200 rpm, the wet mass is tray-dried at 45–50°C for 8–12 h to a moisture endpoint of 3.0–4.5% LOD. The dried mass is milled through a 0.8 mm oscillating sieve and filled into two-piece hypromellose capsules. The capsule formulation uses an API addition ratio of 25–40% w/w granulated extract, to a fill weight of 200–300 mg per size 0 or 1 capsule. A binder solution of 4.0% w/w povidone K30 in 30% v/v ethanol is added during granulation; milled granules are lubricated with 0.5% w/w magnesium stearate for 3–5 min before filling. Terminal products are 150 mg and 250 mg hypromellose capsules for dogs and cats, packed in 10 or 30 count HDPE packs. Compliance references are USP <1094> capsule disintegration, Ph. Eur. 2.9.1 disintegration, USP <2040> dissolution, and VICH GL45 stability. The operational boundary is the hygroscopicity of the granulate: storage relative humidity above 55% RH softens hypromellose shells and activates residual pectin, so blistering or HDPE packs with desiccant are required. The granulate is not suitable for capsules smaller than size 1 without particle size reduction to 0.4 mm, which deteriorates flowability below 0.7 g/s through a standard funnel and requires force-feeding on dosator-type capsule machines.